RxDoctor Payments Data

Jemina Liverman

Psychiatric/Mental Health · Newport News, VANPI 1073889697

Payments from drug & device makers

$4,842in general payments, 2019–2025

Across 106 payments — averaging $45.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • AbbVie$1K
  • Neurocrine Biosciences, Inc.$382
  • Teva Pharmaceuticals USA, Inc.$293
  • Otsuka America Pharmaceutical, Inc.$290
  • E.r. Squibb & Sons, L.L.C.$144
  • plus $843 from 8 others

What the payments were for

  • Speaking & faculty fees$82517%
  • Food & beverage$3,96882%
  • Education$491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,842 in reported general payments places this provider in the 90th percentile of 1,003 psychiatric/mental health providers in Virginia.

See all psychiatric/mental health providers in Virginia

Medicare billing

Part B allowed, 2024
$31,938
Medicare patients
71
Services billed
348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate45$122,324
RexultiBrexpiprazole16$22,353
Aripiprazole78$19,180
CaplytaLumateperone Tosylate11$18,629
Chlorpromazine Hcl25$16,570
Divalproex Sodium124$9,286
Ziprasidone Hcl46$8,639
Divalproex Sodium ErDivalproex Sodium89$6,821
Clozapine61$6,621
Risperidone164$4,457
Quetiapine Fumarate ErQuetiapine Fumarate21$3,643
Lorazepam211$3,485
Risperidone OdtRisperidone18$3,350
Haloperidol105$3,118
Olanzapine100$3,080

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$109$122,32445 claims
Otsuka America Pharmaceutical, Inc.Rexulti$290$22,35316 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,501$18,62911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,003 psychiatric/mental health providers in Virginia.

Other psychiatric/mental health in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →